Skip to content
Medical Health Aged Care, Science

Discovery boosts fight against antibiotic-resistant hospital superbugs

Monash University 3 mins read

Researchers have discovered how a bacteria found in hospitals uses ‘nano-weapons’ to enable their spread, unlocking new clues in the fight against antibiotic-resistant superbugs.

 

Published in Nature Communications, the Monash Biomedicine Discovery Institute (BDI)-led study investigated the common hospital bacterium, Acinetobacter baumannii.

 

A. baumannii is particularly dangerous as it is often resistant to common antibiotics, making infections hard to treat. Due to this, the World Health Organization has listed it as a top-priority critical bacterium, where new treatments are urgently needed.

 

Co-first author and BDI research fellow Dr Marina Harper explained that bacteria rarely exist alone; like plants and animals, different types compete for space and resources. “In many environments, A. baumannii must engage in bacterial ‘warfare’ to survive in the presence of other species,” Dr Harper said.

 

“To outcompete surrounding bacteria, A. baumannii (and many other bacteria) use a nano-weapon called the Type VI Secretion System (T6SS). This is a tiny needle-like machine that injects toxins directly into nearby bacteria, killing them so that A. baumannii can dominate.”

 

Co-first author and BDI research fellow Dr Brooke Hayes said the study investigated how this needle-like machine worked in A. baumannii. “Using advanced microscopy on a highly purified bacterial protein, we discovered the molecular structure of a key toxin from a hospital strain of A. baumannii,” Dr Hayes said.

 

“We learned how this toxin, called Tse15, is attached to the needle and then delivered into other bacteria to kill them. We showed that the toxin is stored in a protective cage-like structure inside A. baumannii, preventing it from harming the bacterium itself. When ready to attack other bacteria, the toxin must be released from the cage.

 

“This happens through a series of interactions between the toxin, the exterior of the cage, and the T6SS needle. Once the needle injects the toxin into a competitor, the toxin activates and kills the other bacterium, allowing A. baumannii to take over that surface.”

 

Senior authors Professor John Boyce, who leads the BDI Boyce Laboratory, and Associate Professor Sheena McGowan, who heads the BDI Structural Microbiology Group, said the find was a significant step in the fight against antibiotic-resistant superbugs.

 

“This discovery is the first time we've understood what the toxin Tse15 looks like, but also the molecular level details of how it and similar toxins are delivered by this bacterial nanomachine,” Professor Boyce said.

 

Associate Professor McGowan added: “Understanding how such toxins are delivered may allow us to engineer new protein toxins for delivery into bacteria. By learning how this system works, we can explore new ways to fight against antibiotic resistant bacteria like A. baumannii.”

 

Read the full paper published in Nature Communications, titled Structure of a Rhs effector clade domain provides mechanistic insights into type VI secretion system toxin delivery

DOI: https://doi.org/10.1038/s41467-024-52950-x          

For media enquiries please contact:

 

Monash University

Cheryl Critchley – Media and Communications Manager (medical)
E:
[email protected]

T: +61 (0) 477 571 442

 

For more Monash media stories, visit our news and events site 


For general media enquiries please contact:
Monash Media
E: 
[email protected]
T: +61 (0) 3 9903 4840

 

About the Monash Biomedicine Discovery Institute

Committed to making the discoveries that will relieve the future burden of disease, the Monash Biomedicine Discovery Institute (BDI) at Monash University brings together more than 120 internationally-renowned research teams. Spanning seven discovery programs across Cancer, Cardiovascular Disease, Development and Stem Cells, Infection, Immunity, Metabolism, Diabetes and Obesity, and Neuroscience, Monash BDI is one of the largest biomedical research institutes in Australia. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.

 

 

***ENDS***

 

 

 

Media

More from this category

  • Medical Health Aged Care, Research Development
  • 11/07/2025
  • 16:28
The Florey

Harnessing mRNA to prevent and slow Alzheimer’s disease

mRNA Victoria funds 2Floreyprojects to prevent and treat Alzheimer’s disease Key points mRNA Victoria has funded 2 Alzheimer’s disease research projects that could position Victoria as a leader in the development of mRNA-based therapies. Dr Abdel Belaidi will develop an mRNA-based system that crosses the blood-brain barrier and aims to slow or even halt disease progression. Dr Rebecca Nisbet will develop an mRNA vaccine that aims to prevent Alzheimer’s disease from developing. Florey researchers working at the cutting edge of dementia research have received funding from mRNA Victoria to develop treatments and a vaccine for Alzheimer’s disease. Since mRNA vaccines…

  • Medical Health Aged Care
  • 11/07/2025
  • 07:05
Royal Australian College of GPs

GPs urge Tasmanian families to get vaccinated against whooping cough and call for free shots to reduce barriers

The Royal Australian College of GPs (RACGP) is urging Tasmanian families to get vaccinated against pertussis, or ‘whooping cough’ and called on all parties and candidates running in the state election to commit to making the vaccination free for all patients. From 1 January 2024 to April 2025, 1238 whooping cough cases were notified in Tasmania, including 10 infants aged under six months. Most hospitalisations and deaths occur in this group, who are not old enough to have received all vaccine doses. More than 21,000 infections were recorded nationwide last year, compared to just 2450 in 2023, and the National…

  • Contains:
  • General News, Medical Health Aged Care
  • 11/07/2025
  • 07:00
La Trobe University

La Trobe researchers awarded $4.5 million in ARC Future Fellowships

LaTrobe University researchers have secured almost $4.5 million in Federal Government funding to further studies into areas such as immune cell development, Australian history and agriculture. Four researchers received an Australian Research Council (ARC) Future Fellowship 2025. The prestigious Future Fellowships support high quality research in areas of national and international benefit, including in national research priorities. Dr Lisa Mielke, from the School of Cancer Medicine, the La Trobe Institute of Molecular Science (LIMS) and the Olivia Newton-John Cancer Research Institute (ONJCRI), received $1.13 million to identify new molecules for future drug and vaccine development to improve gut health in…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.